Eton Pharmaceuticals/$ETON
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Ticker
$ETON
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
31
ISIN
US29772L1089
Website
ETON Metrics
BasicAdvanced
$388M
-
-$0.18
1.28
-
Price and volume
Market cap
$388M
Beta
1.28
52-week high
$21.48
52-week low
$3.22
Average daily volume
578K
Financial strength
Current ratio
1.971
Quick ratio
1.334
Long term debt to equity
123.022
Total debt to equity
123.337
Interest coverage (TTM)
-0.63%
Profitability
EBITDA (TTM)
0.003
Gross margin (TTM)
58.49%
Net profit margin (TTM)
-9.49%
Operating margin (TTM)
-3.83%
Effective tax rate (TTM)
-1.98%
Revenue per employee (TTM)
$1,560,000
Management effectiveness
Return on assets (TTM)
-2.02%
Return on equity (TTM)
-22.95%
Valuation
Price to revenue (TTM)
7.827
Price to book
15.85
Price to tangible book (TTM)
-41.09
Price to free cash flow (TTM)
-145.478
Free cash flow yield (TTM)
-0.69%
Free cash flow per share (TTM)
-9.93%
Growth
Revenue change (TTM)
40.88%
Earnings per share change (TTM)
-658.86%
3-year revenue growth (CAGR)
58.61%
3-year earnings per share growth (CAGR)
-28.93%
What the Analysts think about ETON
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
Bulls say / Bears say
Eton Pharmaceuticals reported record product revenue of $11.6 million in Q4 2024, a 59% increase over Q4 2023, marking the 16th consecutive quarter of sequential product sales growth. (Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results)
The company submitted a New Drug Application (NDA) for ET-600 (Desmopressin Oral Solution) in April 2025, targeting the treatment of central diabetes insipidus, with a potential Q1 2026 launch. (Eton Pharmaceuticals Announces Submission of NDA for ET-600)
Eton expanded its rare disease portfolio by acquiring Galzin® (zinc acetate) Capsules, FDA-approved for Wilson disease, and launched it commercially in March 2025, aiming to significantly expand patient access. (Eton Pharmaceuticals Announces Commercial Launch of Galzin®)
Eton reported a net loss of $0.6 million in Q4 2024, indicating ongoing financial challenges despite revenue growth. (Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results)
The company announced an extension of the PDUFA goal date for ET-400 in February 2025, potentially delaying its market entry and associated revenues. (Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400)
Eton's cash and cash equivalents decreased to $14.9 million as of December 31, 2024, down from $21.4 million the previous year, which may impact its ability to fund future operations and development projects. (Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
ETON Financial Performance
Revenues and expenses
ETON Earnings Performance
Company profitability
ETON News
AllArticlesVideos
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
GlobeNewsWire·1 week ago
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Benzinga·1 month ago
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eton Pharmaceuticals stock?
Eton Pharmaceuticals (ETON) has a market cap of $388M as of July 04, 2025.
What is the P/E ratio for Eton Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eton Pharmaceuticals (ETON) stock is 0 as of July 04, 2025.
Does Eton Pharmaceuticals stock pay dividends?
No, Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Eton Pharmaceuticals dividend payment date?
Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders.
What is the beta indicator for Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.